Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Review topic
No spam. Unsubscribe anytime.
PDAB reviews preliminary 2026 drug and insulin lists based on 2024 insurer reporting
Summary
The board reviewed updated preliminary lists of prescription drugs and insulin products for the 2026 drug review; the lists and an interactive data dashboard were posted based on commercial insurer reporting from calendar year 2024.
The Oregon Prescription Drug Affordability Board reviewed updated preliminary lists of prescription drugs and insulin products for its 2026 drug review. The minutes state the lists and a data dashboard are posted on the PDAB website and were compiled from commercial insurer reporting for calendar year 2024.
Board members discussed the updated preliminary lists as part of the drug-review agenda. The minutes do not record line-by-line list content in the meeting text; the posted dashboard and preliminary lists are the authoritative source for the specific drugs and insulin products under review. The board plans to finalize recommendations and the drug review report at its March meeting.
